Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Maria Elisa Mancuso: Next-Generation Protein Therapies in Hemophilia
Nov 18, 2026, 13:32

Maria Elisa Mancuso: Next-Generation Protein Therapies in Hemophilia

Maria Elisa Mancuso, Professor of Medicine at Frankfurt University Hospital, Medical Specialist at Humanitas Research Hospital, shared a post on LinkedIn:

“WFH New Technology and Gene Therapy Workshop 2026 | Session 1 – New Protein Technologies

Beyond conventional factor replacement: the next generation of protein-based therapies for hemophilia.

An exciting opening scientific session, moderated by Steve Pipe, highlighting how innovative protein engineering and novel mechanisms of action are transforming the therapeutic landscape of hemophilia.

  • Maria Elisa Mancuso discussed the rapidly evolving field of factor VIII mimetics, exploring next-generation molecules designed to reproduce FVIIIa cofactor activity through different molecular architectures and mechanisms of action.
  • Jacob Lund presented the prospects for oral FVIII mimetics, an innovative approach that could potentially transform treatment administration and reduce the burden of prophylaxis.
  • Cedric Hermans explored ultra-long-acting FVIII technologies, focusing on sustained activity and new pharmacokinetic evaluation approaches that may further optimize protection against bleeding.
  • Davide Matino provided an overview of rebalancing agents for hemophilia A and B, including emerging targets such as activated protein C and protein S while addressing the challenges of balancing hemostatic efficacy, thrombotic safety, and individualized treatment strategies.

The key takeaway?

The future of hemophilia treatment is increasingly moving beyond traditional factor replacement towards therapies with novel mechanisms, improved convenience, and potentially more sustained hemostatic protection.

Understanding the distinct pharmacological and biological characteristics of these emerging therapies will be essential to translating innovation into meaningful clinical benefits.

A stimulating session demonstrating how protein engineering continues to expand therapeutic opportunities for people with hemophilia!”

Stay updated with Hemostasis Today.